Testing Platelet Activation With a Shear-Dependent Platelet Function Test Versus Aggregation-Based Tests
Key result
The Cone and Platelet Analyzer (CPA) correlated better with free GP IIb/IIIa receptors than aggregometry or RPFA and detected prolonged platelet inhibition up to 1 week after abciximab.
Why the study?
Does the Cone and Platelet Analyzer (CPA) better reflect platelet function and GP IIb/IIIa receptor occupancy compared to aggregometry and RPFA after abciximab administration?
Population
Blood samples tested in vitro with increasing concentrations of abciximab and ex vivo after abciximab…
Comparison
Cone and Platelet Analyzer vs In vitro platelet aggregometry and Rapid…
Design
Other
Follow-up
up to 1 week (ex vivo)
Authors
Discussion
Loading...
Member takes
Implication
CPA may refine post-abciximab monitoring under shear; leaves open clinical superiority over aggregometry pending validation.
Structured PICO
Does the Cone and Platelet Analyzer (CPA) better reflect platelet function and GP IIb/IIIa receptor occupancy compared to aggregometry and RPFA after abciximab administration?
P
Population
Blood samples tested in vitro with increasing concentrations of abciximab (0% to 100% receptor occupancy) and ex vivo after abciximab administration
E
Exposure
Cone and Platelet Analyzer (CPA) (shear-dependent platelet function test)
C
Comparator
In vitro platelet aggregometry and Rapid Platelet Function Assay (RPFA)
O
Outcome
Correlation with the percentage of free GP IIb/IIIa receptors and detection of prolonged platelet inhibitionsurrogate
The Cone and Platelet Analyzer provides a reliable, baseline-independent method to monitor GP IIb/IIIa inhibition under high shear conditions.
Cite This Study
Fuster et al. (2001) studied Glycoprotein IIb/IIIa inhibition. Cone and Platelet Analyzer (CPA) vs. In vitro platelet aggregometry and Rapid Platelet Function Assay (RPFA) was evaluated on Correlation with the percentage of free GP IIb/IIIa receptors. The Cone and Platelet Analyzer (CPA) correlated better with free GP IIb/IIIa receptors than aggregometry or RPFA and detected prolonged platelet inhibition up to 1 week after abciximab.